Biontech SE
BNTX
View Detailed Chart
93.810USD
-1.000-1.05%
Close 12/15, 16:00（ET）Quotes delayed by 15 min
22.56BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.05%
5 Days
-3.57%
1 Month
-9.00%
6 Months
-11.97%
Year to Date
-17.67%
1 Year
-22.07%
View Detailed Chart
TradingKey Stock Score of Biontech SE
Currency: USD Updated: 2025-12-15Key Insights
Biontech SE's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 82/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 136.96.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Biontech SE's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
22
analysts
Buy
Current Rating
136.958
Target Price
+40.79%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Biontech SE Highlights
StrengthsRisks
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -46.10, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 54.72M shares, decreasing 0.02% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 66.49K shares of this stock.
Biontech SE News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Biontech SE Info
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Ticker SymbolBNTX
CompanyBiontech SE
CEOSahin (Ugur)
Websitehttps://www.biontech.com/
FAQs
What is the current price of Biontech SE (BNTX)?
The current price of Biontech SE (BNTX) is 93.810.
What is the symbol of Biontech SE?
The ticker symbol of Biontech SE is BNTX.
What is the 52-week high of Biontech SE?
The 52-week high of Biontech SE is 129.270.
What is the 52-week low of Biontech SE?
The 52-week low of Biontech SE is 81.200.
What is the market capitalization of Biontech SE?
The market capitalization of Biontech SE is 22.56B.
What is the net income of Biontech SE?
The net income of Biontech SE is -665.30M.
Is Biontech SE (BNTX) currently rated as Buy, Hold, or Sell?
According to analysts, Biontech SE (BNTX) has an overall rating of Buy, with a price target of 136.958.
What is the Earnings Per Share (EPS TTM) of Biontech SE (BNTX)?
The Earnings Per Share (EPS TTM) of Biontech SE (BNTX) is -2.035.
Related Instruments
+3.38%
+1.22%
+1.85%
+1.93%
+1.98%
-0.04%
+2.38%
+0.38%
+2.24%
-0.51%
-1.77%
+0.81%
+3.59%
+1.13%
+0.88%
+3.26%
+1.53%
0.00%
+1.96%
-3.07%
